DEF: Decoy Therapeutics Sets July 14, 2026 Annual Meeting Date

Decoy Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 14, 2026, to elect directors, vote on executive compensation, and ratify auditor appointment.

Summary

• Decoy Therapeutics Inc. is holding its 2026 Annual Meeting of Stockholders on July 14, 2026, via live audio webcast.
• The meeting agenda includes the election of three Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of May 22, 2026, are entitled to vote.
• The Board of Directors recommends voting FOR the director nominees, FOR the executive compensation approval, and FOR the ratification of the auditor appointment.
• Proxy materials will be provided via the Notice and Access method, with paper copies available upon request.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and upcoming shareholder votes, indicating ongoing operational activity and adherence to regulatory requirements.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The Board of Directors is recommending approval of key proposals, indicating confidence in current management and strategy.
• Ernst & Young LLP, a reputable accounting firm, is proposed for reappointment, suggesting continued focus on financial integrity.
• The company is utilizing the Notice and Access method for proxy materials, which is environmentally friendly and cost-effective.

Negatives

• The filing does not contain financial performance data, as it is a proxy statement for an upcoming meeting.
• The company's net loss increased in 2025 compared to 2024, primarily due to the merger closing.

Risks

• The staggered three-year terms for directors may delay or prevent a change in management or control of the company.
• The company's financial statements are prepared in accordance with U.S. generally accepted accounting principles, but the filing itself does not provide current financial performance metrics.
• The company has a clawback policy that requires recoupment of excess incentive-based compensation in the event of a financial restatement due to material non-compliance.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines upcoming proposals for the Annual Meeting of Stockholders, including director elections, executive compensation approval, and auditor ratification.

Management Comments

• The Board of Directors recommends that stockholders vote FOR each of the director nominees listed in Proposal 1 and FOR Proposals 2 and 3.
• The Board of Directors believes that the composition and functioning of its Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee comply with all applicable requirements.
• The Board of Directors believes that the level of director compensation should be based on time spent carrying out Board and committee responsibilities and be competitive with comparable companies, while also aligning director interests with long-term stockholder interests.

Industry Context

StockSavvy.ai notes that Decoy Therapeutics Inc. is operating within the biotechnology sector, a field characterized by significant research and development, regulatory hurdles, and a focus on long-term value creation. The proxy statement's focus on director elections, executive compensation, and auditor ratification is standard for companies in this industry as they navigate growth and potential future financing or strategic events.

Comparison to Industry Standards

• The director compensation structure, with retainers for board service and additional fees for committee chairs and members, aligns with common practices in the biotechnology industry.
• The company's use of a virtual annual meeting is becoming increasingly standard across industries, including biotech, for accessibility and cost-efficiency.
• The structure of the Board of Directors into three classes with staggered terms is a common governance practice aimed at ensuring continuity and stability, though it can also be seen as a defensive measure against hostile takeovers, a consideration relevant in the M&A-active biotech space.

Management Changes

Corporate Governance

Related Party Transactions

• The merger with Legacy Decoy involved executive officers and founders of Legacy Decoy receiving shares and options in the combined company.
• As of December 31, 2025, an officer/founder had an outstanding Demand Note of $55,555 plus accrued interest, with an agreement to exchange it for Series B Preferred Stock contingent upon the Merger closing.
• As of December 31, 2025, a family member of an officer/founder had an outstanding Demand Note of $83,333 plus accrued interest and a Promissory Note of $100,000 plus accrued interest, with agreements to exchange them for Series B Preferred Stock contingent upon the Merger closing.
• Founders of Legacy Decoy loaned approximately $140,000 through non-interest bearing notes during the second half of 2024 and first half of 2025, which were amended to mature in November 2026.

Stakeholder Impact

• Shareholders: Will vote on director elections and executive compensation, influencing corporate governance and management alignment.
• Management and Employees: Executive compensation is subject to advisory shareholder approval; equity awards are designed to retain and incentivize.
• Auditors (Ernst & Young LLP): Appointment is subject to shareholder ratification, impacting the company's financial reporting oversight.

Next Steps

• Stockholders to vote on the election of three Class II directors.
• Stockholders to vote on the non-binding advisory approval of executive compensation.
• Stockholders to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.
• Final voting results to be published in a Form 8-K within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a proxy statement for an upcoming annual meeting and does not contain new financial performance data or strategic announcements that would warrant a buy or sell recommendation. It outlines standard corporate governance procedures and proposals for shareholder vote. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position pending further material developments.

Keywords

Decoy Therapeutics, Proxy Statement, Annual Meeting, DEF 14A, Director Election, Executive Compensation, Auditor Ratification, Stockholder Vote, Corporate Governance